Please wait while we load the requested 10-Q report or click the link below:
Altimmune Announces First Quarter 2018 Financial Results and Provides
Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET
GAITHERSBURG, MD, May 15, 2018 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three months ended March 31, 2018.
Recent Corporate Highlights
|||Announced positive proof-of-concept data from its Phase 2a intranasal flu vaccine trial with NasoVAX vaccine when compared with a licensed injectable seasonal flu vaccine;|
|||Announced positive pre-clinical data for survival and immunogenicity from the Companys Phase 2 SparVax-L program when compared against BioThrax to prevent anthrax infection;|
|||Extended its IP protection of NasoShield in the U.S. with a Notice of Allowance from the U.S. Patent Office; and|
|||Consolidated multiple Gaithersburg sites, including laboratory buildout, into new headquarters in Gaithersburg.|
We have had a very data-rich few months with results being reported from our NasoVAX, HepTcell, and SparVax-L programs, said William J. Enright, Chief Executive Officer of Altimmune. The positive results from our NasoVAX trial give us strong confidence that we have a truly novel approach to combat flu and we look forward to getting Phase 2b clinical trials started next year. NasoVAX has tremendous potential as an effective, easy-to-administer flu vaccine that could provide better protection than current vaccines.
We are also excited by the results on our SparVax-L study where two doses of SparVax-L produced levels of protective immunity that were significantly greater than that obtained following two doses of the licensed vaccine and we look forward to moving that program forward once we secure additional government funding, Mr. Enright added. We continue to evaluate our HepTcell results and will update investors on our next steps after we complete the data analysis from the remaining timepoints and better understand our initial results. Operationally, we are focused on executing and moving our programs forward towards licensure as we believe our vaccines offer significant advantages.
The following information was filed by Altimmune, Inc. (ALT) on Tuesday, May 15, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Altimmune, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Altimmune, Inc..